Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of IBI362 in Chinese Adolescents With Obesity or Overweight
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Summary
The study is designed to assess the efficacy and safety of multiple doses of IBI362 in Chinese adolescent subjects with obesity or overweight. It plans to enroll 180 adolescents (aged ≥12 and \<18 years) who have failed to achieve a 5 kg weight reduction after at least 12 weeks of dietary and exercise intervention.
Official title: A Randomized, Double-blind, Placebo-controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of IBI362 in Chinese Adolescents With Obesity or Overweight（GLORY-YOUNG）
Key Details
Gender
All
Age Range
12 Years - 18 Years
Study Type
INTERVENTIONAL
Enrollment
180
Start Date
2025-12-29
Completion Date
2028-10-31
Last Updated
2026-01-08
Healthy Volunteers
No
Interventions
Placebo
Placebo SA.QW
IBI362
IBI362 SA.QW
Locations (1)
The Children's Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China